TSE:RVX

Resverlogix - RVX Stock Forecast, Price & News

C$0.16

-0.01 (-5.88%)

(As of 03/23/2023 09:01 PM ET)

Add

Compare

Today's Range: C$0.16
▼
C$0.17
50-Day Range: C$0.13
▼
C$0.25
52-Week Range: C$0.12
▼
C$0.53

Volume: 69,500 shs
Average Volume: 53,556 shs
Market Capitalization: C$42.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Resverlogix (TSE:RVX) Stock

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Receive RVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter.

RVX Stock News Headlines

March 20, 2023 | msn.com

Resverlogix extends debenture maturity by one year

March 2, 2023 | finance.yahoo.com

Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19

March 27, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

December 11, 2022 | finance.yahoo.com

Insiders who bought in the last 12 months lose an additional US$43k as Resverlogix Corp. (TSE:RVX) drops to CA$44m

September 30, 2022 | globenewswire.com

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone's Future Development for the Prevention and Treatment of Post COVID-19 Conditions - GlobeNewswire

September 30, 2022 | finance.yahoo.com

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

September 28, 2022 | globenewswire.com

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions - GlobeNewswire

September 28, 2022 | finance.yahoo.com

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

March 27, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

September 15, 2022 | reuters.com

RVX.TO - Resverlogix Corp. | Stock Price & Latest News | Reuters

August 22, 2022 | globenewswire.com

Resverlogix Publishes New Data Highlighting Apabetalone's - GlobeNewswire

August 22, 2022 | finance.yahoo.com

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

August 16, 2022 | globenewswire.com

Resverlogix Announces Appointment of New Chief Scientific Officer - GlobeNewswire

August 15, 2022 | finance.yahoo.com

Resverlogix Announces Appointment of New Chief Scientific Officer

August 1, 2022 | globenewswire.com

Pulmonary Hypertension Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight - GlobeNewswire

July 10, 2022 | theglobeandmail.com

Resverlogix Corp stock decreased on Friday.

July 5, 2022 | finance.yahoo.com

WSJ Opinion: An Historic Term for the Supreme Court - Yahoo Finance

July 4, 2022 | finance.yahoo.com

A Resverlogix Corp. (TSE:RVX) insider increased their holdings by 7.8% last year - Yahoo Finance

July 3, 2022 | finance.yahoo.com

A Resverlogix Corp. (TSE:RVX) insider increased their holdings by 7.8% last year

June 22, 2022 | globenewswire.com

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders - GlobeNewswire

June 8, 2022 | globenewswire.com

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors - GlobeNewswire

June 8, 2022 | finance.yahoo.com

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

May 9, 2022 | globenewswire.com

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study - GlobeNewswire

May 9, 2022 | finance.yahoo.com

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

April 21, 2022 | finance.yahoo.com

Resverlogix Announces One-Year Extension of Debenture - Yahoo Finance

April 19, 2022 | finance.yahoo.com

Read Statistics on Global Aramid Fiber Market Share & Size to Surpass USD 6,070.8 Million by 2028, Exhibit a CAGR of 9.5% - Industry Trends, Analysis, & Forecast Report by Facts & Factors - Yahoo Finance

April 19, 2022 | globenewswire.com

Resverlogix Announces One-Year Extension of Debenture - GlobeNewswire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter.

RVX Company Calendar

Today: 3/27/2023
Next Earnings (Estimated): 3/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:RVX
CUSIP: N/A
CIK: N/A
Web: www.resverlogix.com
Phone: +1-403-2549252
Fax: N/A
Employees: 25
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.16
Quick Ratio: 0.04

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.00 per share
Price / Cash Flow: 132.50
Book Value: C($0.23) per share
Price / Book: -0.70

Miscellaneous

Outstanding Shares: 265,270,000
Free Float: N/A
Market Cap: C$42.44 million
Optionable: Not Optionable
Beta: 0.48

Key Executives

Mr. Donald J. McCaffrey
Co-Founder, Chairman, Pres, CEO & Sec.

Mr. Aaron Bradley Cann C.A.
CPA, CA, CPA, CBV, Chief Financial Officer

Dr. Ewelina Kulikowski Ph.D.
Chief Scientific Officer

Dr. Jan O. Johansson M.D.
Ph.D., Sr. VP of Medical Affairs

Dr. Michael Sweeney M.D. (Age 62)
Sr. VP of Clinical Devel.
Comp: $492.91k

Sarah Zapotichny
Director of Investor Relations & Corp. Communications

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

RVX Stock - Frequently Asked Questions

How have RVX shares performed in 2023?: Resverlogix's stock was trading at C$0.14 at the beginning of the year. Since then, RVX shares have increased by 14.3% and is now trading at C$0.16.
View the best growth stocks for 2023 here.
When is Resverlogix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our RVX earnings forecast.
What other stocks do shareholders of Resverlogix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT), Endocyte (ECYT), Allena Pharmaceuticals (ALNA), Catalyst Pharmaceuticals (CPRX) and Royalty Pharma (RPRX).
What is Resverlogix's stock symbol?: Resverlogix trades on the Toronto Stock Exchange (TSX) under the ticker symbol "RVX."

How do I buy shares of Resverlogix?: Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Resverlogix's stock price today?: One share of RVX stock can currently be purchased for approximately C$0.16.
How much money does Resverlogix make?: Resverlogix (TSE:RVX) has a market capitalization of C$42.44 million. The biotechnology company earns C$-21,310,000.00 in net income (profit) each year or C($0.13) on an earnings per share basis.
How can I contact Resverlogix?: Resverlogix's mailing address is 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada. The official website for the company is www.resverlogix.com. The biotechnology company can be reached via phone at +1-403-2549252.

This page (TSE:RVX) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial